European journal of gastroenterology & hepatology
Cure8 research brief
Why This Matters
For people with Crohn's disease who no longer respond to single biologic agents, combining two different biologics (ustekinumab + vedolizumab) may recapture response and lower inflammation markers, offering a possible rescue option worth discussing with an IBD specialist.
Who Should Pay Attention
Adults with Crohn's disease refractory to biologics, patients currently on ustekinumab or vedolizumab who have lost response, IBD clinicians, and researchers studying combination biologic strategies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a small, retrospective study (23 patients) describing a rescue strategy using simultaneous ustekinumab and vedolizumab for people with active Crohn's disease who previously failed each drug alone.
Reported outcomes include clinical response and remission, biomarker improvements (CRP, fecal calprotectin), and endoscopic response in subsets of patients.
Because it is retrospective and uncontrolled, these results are preliminary and cannot establish that the combination is safer or more effective than other options; the authors conclude prospective validation is needed.
If considering combination biologic therapy, discussions with an IBD specialist about individual risks, monitoring, and alternatives are appropriate; this abstract does not provide long-term safety or comparative effectiveness data.
Keep In Mind
This is a retrospective, small (n=23) case series reported as an abstract; it is hypothesis-generating but not definitive. Prospective, controlled trials are needed to confirm efficacy and safety. Endoscopic data were available only for a subset. The study reports mostly mild adverse events but long-term safety is not addressed.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationEuropean journal of gastroenterology & hepatology
AuthorsLu C, Ling T, Li Y +4 more
Study typeIm, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedSep 28, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: Medical and Health Science Program of Zhejiang Province - 2025HY1353
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Beyond Anti-TNF: Is Ustekinumab a Better Choice in Crohn's? - Medscape
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
Current and novel biomarkers for predicting and assessing therapeutic response in inflammatory bowel disease: a systematic review.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Outcomes of risankizumab use in adults with Crohn's disease in a real-world setting (ARISE-CD): a multicentre, retrospective cohort study.
This real-world multicentre study evaluates risankizumab effectiveness and short-term persistence in adults with Crohn's disease, including those previously treated with ustekinumab — information that can help patients...